24.30
+0.3(+1.25%)
Currency In USD
Address
11099 North Torrey Pines Road
San Diego, CA 92037
United States of America
Phone
858 750 4700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
91
First IPO Date
June 11, 2021
| Name | Title | Pay | Year Born |
| Dr. David Alan Campbell Ph.D. | President, Chief Executive Officer & Director | 1.13M | 1960 |
| Mr. Charles M. Winter | Chief Technical Officer | 590,400 | 1970 |
| Dr. Thomas Diraimondo Ph.D. | Chief Scientific Officer | 630,000 | 1987 |
| Mr. Byron Robinson J.D., Ph.D. | Chief Strategy Officer | 727,500 | 1965 |
| Mr. James Pennington | General Counsel & Corporate Secretary | 0 | N/A |
| Ms. Maria Dobek | Principal Accounting Officer & Vice President of Accounting | 0 | 1990 |
| Mr. Andy Hollman Meyer | Chief Business Officer | 0 | 1984 |
| Mr. Matt Whitmire | Vice President of Finance | 0 | N/A |
| Dr. Zachariah McIver D.O., Ph.D. | Chief Medical Officer | 0 | 1970 |
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.